AURAK Study Urges Greater Awareness of Enterovirus Threats in Gulf
A comprehensive study conducted by the American University of Ras Al Khaimah has raised alarms over the under-recognised threat posed by enteroviruses in the Arabian Gulf region, particularly among children. The research underscores the urgent need for enhanced public health surveillance and awareness to mitigate potential outbreaks.
Enteroviruses, a group of RNA viruses, primarily infect the gastrointestinal tract but can lead to severe complications, especially in infants and young children. These complications include aseptic meningitis, encephalitis, myocarditis, and acute flaccid paralysis. Despite their global prevalence, data on enterovirus infections in the Gulf Cooperation Council countries remain scarce, leading to potential underdiagnosis and mismanagement.
The AURAK study highlights that the limited reporting and research on enteroviruses in the region have resulted in a lack of comprehensive understanding of their epidemiology, transmission patterns, and clinical manifestations. This gap hampers the development of effective public health strategies to combat these infections.
One of the significant concerns raised by the study is the vulnerability of children to enterovirus infections. Factors such as crowded living conditions, inadequate hygiene practices, and limited access to healthcare contribute to the increased risk among this demographic. The study emphasizes the importance of targeted interventions to protect children, including public education campaigns and improved sanitation measures.
The research also points to the need for enhanced diagnostic capabilities in the region. Currently, the lack of specialized laboratories and trained personnel limits the ability to accurately identify and monitor enterovirus outbreaks. Investing in laboratory infrastructure and training programs is crucial to improve diagnostic accuracy and response times.
See also Strong Winds and Dust Clouds Disrupt UAE Weather
The study calls for the establishment of a regional surveillance network to monitor enterovirus activity across the GCC countries. Such a network would facilitate the sharing of data, resources, and best practices, enabling a coordinated response to potential outbreaks. Collaboration among public health authorities, academic institutions, and international organizations is essential to build this capacity.
The AURAK researchers recommend that policymakers prioritize enterovirus research and allocate funding to support studies on virus behavior, transmission dynamics, and vaccine development. Understanding the genetic diversity and evolution of enteroviruses is critical to developing effective prevention and treatment strategies.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Arabian Business
14 hours ago
- Arabian Business
Inside Insilico's bid to create the UAE's first homegrown cancer drug
Clinical-stage biotech company Insilico Medicine recently announced it will attempt to discover the first novel cancer drug developed entirely in the United Arab Emirates with just four scientists and its proprietary AI platform to complete work that traditionally takes hundreds of researchers and years of effort. The Abu Dhabi-based team aims to identify promising cancer targets, design new molecules, and prepare a complete preclinical data package within 18 months—a process that typically takes pharmaceutical companies three to five years and costs hundreds of millions of dollars. 'Our Masdar City centre already hosts around 60 AI and biotech specialists. By tasking four of them with a complete end-to-end discovery run, we aim to prove that any GCC nation equipped with cloud compute, wet-lab automation and local talent can create world-class therapeutics,' Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine, told Arabian Business. The initiative represents both a scientific experiment and a geopolitical statement as it has the potential to transform the Middle East's role in global pharmaceutical development while challenging fundamental assumptions about where and how drug discovery can occur in the AI era. Four scientists, one AI The team consists of two computational chemists, one medicinal chemist, and one translational biologist – a deliberately lean operation working alongside Insilico's proprietary AI system, They are targeting what the company describes as 'medium-novelty and genetically validated synthetic-lethality targets' for solid tumours –essentially, seeking ways to kill cancer cells by exploiting specific genetic vulnerabilities. In pharmaceutical terms, the team is working at breakneck speed. Their roadmap calls for finalising a biological target by Q3 2025, generating promising molecular structures in under 30 days, and completing the entire preclinical package within 18 months. Traditional drug discovery typically takes three to five years just to reach the preclinical stage. 'Humans still design strategy and verify results, but AI handles the brute-force search, learns from every experiment in real time, and steers us away from dead ends,' explained Zhavoronkov. His description evokes a chess grandmaster working with a silicon partner—humans providing intuition and judgment, the machine crunching through billions of possibilities. Why the UAE? The choice of Abu Dhabi might seem puzzling at first. The UAE has invested heavily in healthcare infrastructure, but it remains far from established biotech hubs like Boston, San Francisco, or Cambridge. For Zhavoronkov, that's precisely the point. 'The reason we chose the UAE is because we already have a base there,' he said, referring to the AI Research and Development Centre that Insilico opened in Masdar City in 2023 with support from the Abu Dhabi Investment Office. 'UAE scientists helped discover a drug but they never tried to take full control over the drug discovery program.' This initiative – which Zhavoronkov is careful to note is self-funded by Insilico, not UAE government money – is as much about proving a concept as it is about discovering a specific drug. If a small team in Abu Dhabi can successfully identify a viable cancer treatment, it suggests that any country with sufficient computing resources and a small cadre of specialists could potentially develop life-saving medications. 'Not just lucky' Insilico's approach builds on research dating back to 2016, when the company published one of the first papers describing how generative adversarial networks (GANs) – the same AI architecture later used in image generators like DALL-E – could design novel molecules. The biotech landscape is littered with AI companies that promised to revolutionise drug discovery but delivered little. Zhavoronkov seems acutely aware of this skepticism. 'Since 2021 we have nominated 22 development candidates, advanced 10 into the clinic, completed four Phase I trials and a Phase IIa – without a single clinical failure,' he said. 'Those numbers convert skepticism into evidence.' Asked why Insilico has succeeded where others have not, Zhavoronkov pointed to four specific factors: 'Pristine, well-curated data – quantity without quality is noise; a closed experimental loop where every prediction is rapidly tested in-house and fed back to the models; deep integration of AI engineers, biologists and chemists under one roof… and many experimentally-validated AI models that we know worked in real world.' In an industry where approximately 90 per cent of drug candidates fail during development, Insilico's lead drug, Rentosertib, recently showed positive results in a Phase IIa trial for idiopathic pulmonary fibrosis (a serious lung disease that causes scarring of the lungs). The company reported that Rentosertib demonstrated favourable safety and tolerability across all dose levels, with promising early efficacy signals after just 12 weeks of treatment. In January 2025, Nature Biotechnology published a paper detailing Rentosertib's journey from AI algorithms to clinical trials – the first comprehensive account of an AI-discovered and AI-designed drug from initial concept to human testing. The company is already planning to expand across the Gulf region. Insilico recently signed a Memorandum of Understanding with Saudi Arabia's Ministry of Investment and plans to establish an operation in Riyadh by 2026, with partial funding from Aramco's Prosperity7 Ventures. The company is also in discussions with Qatar, Kuwait, Bahrain, and Oman about potential expansion. 'If the pilot hits its timelines, we will deploy identical micro-teams across the region, accelerating the sovereign drug-discovery capabilities where it matters most,' Zhavoronkov said. The bigger picture Beyond regional implications, Insilico's experiment touches on a profound question: does drug discovery still need massive teams, extensive physical infrastructure, and geographical proximity to traditional biotech clusters? 'The goal is to have multiple AI-originated drugs approved and on pharmacy shelves, with a steady stream of new candidates entering the clinic every year,' he said. '[For Insilico Medicine,] success looks like regulators, payers and physicians treating AI-designed medicines as the norm – much like jetliners are now designed in silico.' Alex Aliper, Co-Founder and President of Insilico Medicine, framed the effort in economic terms, suggesting that channelling the Gulf's 'deep technology' investments into 'life-saving medicines offers the fastest way to diversify economies and extend healthy longevity' in the region.
Khaleej Times
2 days ago
- Khaleej Times
Saal.ai and Intertec Systems announce strategic collaboration
a cognitive technology company wholly owned by Abu Dhabi Capital Group (ADCG), and a leader in Artificial Intelligence (AI) and Big Data innovation, has announced a strategic collaboration with Intertec Systems, a regionally recognized digital transformation and cybersecurity solutions provider, to jointly deliver cutting-edge AI and Big Data use cases across the Gulf Cooperation Council (GCC) region. At the core of this partnership is DigiXT – a Made-in-UAE Big Data platform developed by Designed to meet the strategic needs of governments and enterprises in the region, DigiXT empowers clients to extract actionable insights from complex and large-scale data ecosystems while retaining full data sovereignty and operational control. What makes DigiXT uniquely valuable is its flexible deployment capability—it can be implemented both on-premises and on the cloud, giving organizations the confidence to align their digital initiatives with their specific security, compliance, and performance requirements. This level of control ensures that customers benefit from a powerful, scalable, and secure data foundation without compromising on regulatory expectations. The partnership leverages deep domain expertise in AI, machine learning, and data engineering, and combines it with Intertec Systems' strong regional presence, digital & cloud capabilities, and delivery excellence. Founded in 1991, Intertec Systems brings over three decades of success across sectors including public sector, healthcare, utilities, financial services, and enterprises. Vikraman Poduval, CEO of said: 'With DigiXT, we're not just delivering technology—we're enabling digital independence for the region. Intertec's strong local credibility and execution strength make them the ideal partner to scale this impact across the GCC.' For his part, Naresh Kothari, Managing Director, Intertec Systems added: 'This partnership with is a powerful step forward in delivering regionally developed, secure, and intelligent platforms. With digiXT, we aim to help our clients transform faster, smarter, and with greater control.' This collaboration represents a shared commitment to building future-ready digital capabilities, promoting regional innovation, and advancing data-driven transformation underpinned by strategic autonomy and technological excellence.
Gulf Today
4 days ago
- Gulf Today
Female graduates outnumber males at AURAK event
Female graduates outnumbered males at the twin Commencement Ceremonies of the American University of Ras Al Khaimah (AURAK), while Artificial Intelligence (AI) took centre-stage with the number of graduates doubling in just one year. The two graduation ceremonies, 13th and 14th, saw a total of 331 graduate and undergraduate students receive their degrees, of which 188 (56.8 per cent) were female, reflecting the growing trend of women aspiring for careers and entrepreneurship. The second major takeaway was the rising prominence of AI in the career landscape. The ceremony saw the very first batch of the university's Bachelor in Artificial Intelligence receive their degrees. AURAK's Bachelor of Science in AI is a four-year programme that empowers students to design and develop computer systems and data models, using the latest advances in the field. The 13th Graduation Ceremony (Class of 24) had extra significance attached to it, for these graduates had entered university in the thick of COVID-19 disruption, and had to navigate through the unknown territory of online classes. AURAK, listed among Top 500 Universities in the 2025 QS World University Rankings and occupying the sixth position among UAE universities, honoured 68 graduates and 263 undergraduates at the two ceremonies held on successive days. Eight students earned the Summa Cum Laude (highest distinction) honour. Robert Raines, US Consul General in Dubai, who delivered the Commencement Adress, hailed the resilience displayed by the COVID-impacted graduates of the Class of 2024, and urged them to draw inspiration from the Ghaf tree, whose roots go 60 metres into the soil. 'Remember your resilience. Remember that you can do this, whether you become scientists, teachers, entrepreneurs, engineers, artists or diplomats. You're entering a world that faces serious global challenges. You will need your resilience to survive and to succeed, and the world needs you to succeed. Second, I hope that you'll remember the value and the importance of community... because it is your community that will nourish you as you grow,' Robert Raines remarked. Dr David A. Schmidt, President of AURAK, in his welcome address, said: 'The world you are stepping into demands resilience, adaptability and vision. You've proven that you can navigate uncertainty and adapt to the unexpected. You've pursued knowledge, not at the absence of obstacles, but often in the face of them. As we confer your degrees, we do more than acknowledge your academic accomplishments, we affirm your readiness to lead and to shape the future.' Prof Stephen C. Wilhite, Senior Vice President of Academic Affairs and Student Success/Provost, urged the graduates to carry the legacy of appreciation for diversity and a commitment to promoting cultural understanding and to fostering civic responsibility.
